Ad
related to: newest treatment for glioblastoma disease cancer patients
Search results
Results from the WOW.Com Content Network
The primary goal of doubling the number of patients reaching progression-free survival at six months (PFS6) was substantially exceeded. [13] Asunercept has also been successfully tested in a phase I trial to treat patients with MDS. [14] MDS is a disease in which the bone marrow does not make enough healthy blood cells, which leads to blood ...
The Glioblastoma Foundation funds research on discovering new and more effective treatments for glioblastoma patients. Grants are allocated to clinicians and scientists affiliated with institutions including Johns Hopkins Hospital, MD Anderson Cancer Center, and Columbia University.
The purpose of the ReSPECT-GBM Clinical Trial is to assess the safety, tolerability, and distribution of a new medication, Rhenium (186Re) Obisbemeda, in adults with recurrent glioblastoma after standard surgical, radiation, and/or chemotherapy treatment. ReSPECT-GBM is supported by the U.S. National Institutes of Health / National Cancer ...
In this study, patients with glioblastoma that had recurred after initial conventional therapy were randomized to treatment either with a TTFields device (NovoTTF-100A / Optune) or with their treating physician's choice of standard chemotherapy. Survival or response rate in this trial was approximately 6 months, and was not significantly better ...
Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has a very poor prognosis for survival. [ 6 ] [ 7 ] [ 8 ] Initial signs and symptoms of glioblastoma are nonspecific. [ 1 ]
It is also approved for treatment of Hodgkin’s lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy. [8] It is the standard of care for recurrent glioblastoma multiforme in Europe, and it is frequently used as a control arm in recurrent glioblastoma multiforme trials. [23]
[5] [7] She showed that the simple antiviral treatment Valganciclovir could extend the life expectancy of glioblastoma patients by forty months. [ 5 ] [ 8 ] She is leading a double-blind clinical trial to evaluate the efficacy of valganciclovir , an anti-CMV drug, in the treatment of patients with glioblastoma. [ 9 ]
Treatment of Recurrent Malignant Gliomas. The single greatest advance in moving BNCT forward clinically has been the introduction of cyclotron-based neutron sources (c-BNS) in Japan. Shin-ichi Miyatake and Shinji Kawabata have led the way with the treatment of patients with recurrent glioblastomas (GBMs).
Ad
related to: newest treatment for glioblastoma disease cancer patients